Vandetanib
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic Medullary Thyroid Cancer
Conditions
Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer
Trial Timeline
Feb 25, 2011 → Mar 13, 2025
NCT ID
NCT01298323About Vandetanib
Vandetanib is a phase 3 stage product being developed by Sanofi for Locally Advanced or Metastatic Medullary Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01298323. Target conditions include Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01298323 | Phase 3 | Completed |
| NCT00862836 | Phase 1/2 | Terminated |
| NCT00537095 | Phase 2 | Completed |
| NCT00681798 | Phase 1 | Completed |
| NCT00066313 | Phase 2 | Completed |
Competing Products
20 competing products in Locally Advanced or Metastatic Medullary Thyroid Cancer